Overview

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Status:
Terminated

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control. Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients.

Phase:

Phase 2

Details

Lead Sponsor:

Stem Cell Therapeutics Corp.

Treatments:

Chorionic Gonadotropin
Epoetin Alfa